



## Resolution n° 14-2018-e

### “Expand New Drug Markets for TB (endTB)” Project

Recalling Unitaid Executive Board Resolution EB19/SSP/2014/R1 of 5 May 2014, in which the Board approved the commitment of up to US\$ 60,369,772 for the Project entitled “Expand New Drug Markets for TB (endTB)” (the “Project”) implemented by Partners in Health for a four-year period;

Recalling Unitaid Executive Board Resolution UNITAID/2018/R6-e of 25 June 2018, in which the Board provided its go-ahead for the development by the Unitaid Secretariat of a full grant agreement package for the Project to:

- a) Extend the duration of the Project until 31 December 2022 in order to allow for completion of the current clinical trial; and
- b) Expand the scope of the Project to include a new clinical trial targeting FQ-resistant MDR-TB patients, as envisaged in the endTB-Q Proposal submitted by Partners in Health to the Secretariat on 24 August, 2017.

The Executive Board now authorizes the Executive Director to commit an additional amount of up to USD 21,000,000 for the proposed extension and expansion of the Project, subject to availability of funds.

Funding is conditional upon signature of a formal amendment of the grant agreement between Unitaid and Partners in Health.

Lead Organization: Partners in Health

Target countries: India, Lesotho, Kazakhstan, Pakistan, Peru, Kyrgyzstan, South Africa

Extended and Expanded Project Duration: 1 April 2015 – 31 December 2022

Marta Maurás  
Chair of the Unitaid Executive Board

Date: 24 September 2018